IAB22M2C

Drug Profile

IAB22M2C

Alternative Names: 89Zr Df IAB22M2C; IAB 22 M2C

Latest Information Update: 03 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ImaginAb Inc
  • Class Antibody diagnostics; Imaging agents; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer; Graft-versus-host disease

Most Recent Events

  • 01 Jun 2018 Preliminary adverse events and pharmacokinetics data from a phase I trial in Cancer (Diagnosis, Metastatic disease, Second-line therapy or greater) presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
  • 01 Apr 2017 Phase-I clinical trials in Cancer (Diagnosis, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT03107663)
  • 01 Apr 2017 Phase-I clinical trials in Graft-versus-host disease (Diagnosis, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT03107663)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top